MX2019006326A - Derivados de tirosina y composiciones que los comprenden. - Google Patents

Derivados de tirosina y composiciones que los comprenden.

Info

Publication number
MX2019006326A
MX2019006326A MX2019006326A MX2019006326A MX2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A
Authority
MX
Mexico
Prior art keywords
compositions
tyrosine hydroxylase
hydroxylase inhibitor
tyrosine derivatives
subject
Prior art date
Application number
MX2019006326A
Other languages
English (en)
Spanish (es)
Inventor
Hoffman Steven
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of MX2019006326A publication Critical patent/MX2019006326A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2019006326A 2016-11-30 2017-11-30 Derivados de tirosina y composiciones que los comprenden. MX2019006326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
MX2019006326A true MX2019006326A (es) 2019-07-12

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006326A MX2019006326A (es) 2016-11-30 2017-11-30 Derivados de tirosina y composiciones que los comprenden.

Country Status (12)

Country Link
EP (1) EP3548086A1 (enExample)
JP (2) JP2019536783A (enExample)
KR (1) KR20190089191A (enExample)
CN (1) CN110062633A (enExample)
AU (1) AU2017368135A1 (enExample)
BR (1) BR112019011033A2 (enExample)
CA (1) CA3045110A1 (enExample)
EA (1) EA201991305A1 (enExample)
IL (1) IL266840A (enExample)
MX (1) MX2019006326A (enExample)
PH (1) PH12019501186A1 (enExample)
WO (1) WO2018102506A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
KR20220099990A (ko) 2019-11-07 2022-07-14 인3바이오 리미티드 비티로신 표적화 키나아제 억제제와 병용하여 성장 인자 항체를 사용하기 위한 방법 및 조성물
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP3075247B1 (en) * 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
DK2013221T3 (en) * 2006-04-19 2015-09-28 Univ Texas Compositions and methods for cellular imaging and therapy
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
JP2022153587A (ja) 2022-10-12
EP3548086A1 (en) 2019-10-09
JP2019536783A (ja) 2019-12-19
CN110062633A (zh) 2019-07-26
IL266840A (en) 2019-07-31
KR20190089191A (ko) 2019-07-30
AU2017368135A1 (en) 2019-06-13
WO2018102506A1 (en) 2018-06-07
EA201991305A1 (ru) 2019-10-31
PH12019501186A1 (en) 2020-02-10
BR112019011033A2 (pt) 2019-10-15
CA3045110A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12019501186A1 (en) Tyrosine derivatives and composition comprising them
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MY195110A (en) Antibodies to PD-1 and uses Thereof
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
MX2022012937A (es) Conjugados de afinidad-oligonucleotido y usos de los mismos.
EP4458418A3 (en) Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MY199019A (en) Pd-1 antibodies
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
EP4613332A3 (en) Cot modulators and methods of use thereof
TWD173671S (zh) 通訊耳機之部分
AU2017260389A1 (en) Chimeric neurotoxins
EP4389142A3 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
CR20110553A (es) Terapia complementaria contra el cáncer
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
WO2017132746A8 (en) Ubiquitin variants and uses thereof as 53bp1 inhibitors
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
MX2019013642A (es) Compuestos, composiciones y metodos.
MX2017011521A (es) Composiciones topicas que comprenden un corticosteroide.
MX2021008839A (es) Composiciones aglomerantes y metodos para fabricacion y uso de las mismas.
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
MX380547B (es) Composición que comprende un inhibidor de fgfr1/kdr micronizado y el uso del mismo en el tratamiento de tumores neuroendocrinos.
GB2543709A (en) Pharmaceutical agent